Alaunos Therapeutics, Inc. (TCRT)
1.855
+0.02
(+0.82%)
USD |
NASDAQ |
Nov 06, 10:23
Alaunos Therapeutics Enterprise Value : 4.450M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 4.450M |
| November 04, 2026 | 4.351M |
| November 03, 2026 | 4.500M |
| November 02, 2026 | 4.227M |
| October 30, 2026 | 4.724M |
| October 29, 2026 | 4.575M |
| October 28, 2026 | 5.171M |
| October 27, 2026 | 4.997M |
| October 26, 2026 | 5.171M |
| October 23, 2026 | 5.544M |
| October 22, 2026 | 7.434M |
| October 21, 2026 | 7.533M |
| October 20, 2026 | 7.260M |
| October 19, 2026 | 7.658M |
| October 16, 2026 | 6.414M |
| October 15, 2026 | 5.296M |
| October 14, 2026 | 5.022M |
| October 13, 2026 | 7.409M |
| October 12, 2026 | 2.486M |
| October 09, 2026 | 1.830M |
| October 08, 2026 | 1.818M |
| October 07, 2026 | 1.960M |
| October 06, 2026 | 1.722M |
| October 05, 2026 | 1.853M |
| October 02, 2026 | 1.915M |
| Date | Value |
|---|---|
| October 01, 2026 | 2.163M |
| September 30, 2026 | 2.082M |
| September 29, 2026 | 2.264M |
| September 28, 2026 | 2.412M |
| September 25, 2026 | 2.586M |
| September 24, 2026 | 2.685M |
| September 23, 2026 | 2.735M |
| September 22, 2026 | 3.033M |
| September 21, 2026 | 3.008M |
| September 18, 2026 | 2.859M |
| September 17, 2026 | 3.854M |
| September 16, 2026 | 3.058M |
| September 15, 2026 | 3.381M |
| September 14, 2026 | 3.580M |
| September 11, 2026 | 3.63M |
| September 10, 2026 | 3.753M |
| September 09, 2026 | 3.754M |
| September 08, 2026 | 3.779M |
| September 04, 2026 | 3.928M |
| September 03, 2026 | 3.978M |
| September 02, 2026 | 4.028M |
| September 01, 2026 | 4.003M |
| August 31, 2026 | 4.102M |
| August 28, 2026 | 3.866M |
| August 27, 2026 | 4.003M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 539.10M |
| Amgen, Inc. | 289.78B |
| Anika Therapeutics, Inc. | 245.53M |
| BioCryst Pharmaceuticals, Inc. | 2.407B |
| Imunon, Inc. | 5.181M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.952M |
| Total Expenses (Quarterly) | 0.952M |
| EPS Diluted (Quarterly) | -0.4063 |
| Earnings Yield | -105.0% |
| Normalized Earnings Yield | -105.02 |